title: Serum IL10, IL12 and circulating CD4+CD25high T regulatory cells in             relation to long-term clinical outcome in head and neck squamous cell carcinoma             patients.
abstract: IL10, but not IL12 or T regulatory cells in the circulation of newly presenting,             pre-treatment head and neck squamous cell carcinoma (HNSCC) patients, has been             shown previously to be related to survival over a mean follow-up period of 15 months.             Here, we followed the same patients for a longer period to determine whether these             associations change. Pre- and post-treatment serum IL10/IL12 and circulating T             regs were measured using ELISA and flow cytometry respectively and were correlated             with survival after a 33 month average follow-up in a cohort of newly presenting             HNSCC patients (n=107), with cancers of the hypopharynx (n=16), larynx (n=36),             oral cavity (n=21), oropharynx (n=25), sinonasal (n=4) or unknown origin (n=5).             Although the mean survival time of patients with detectable levels of IL10 pre-treatment             was lower (40.6 months) than that of those without detectable levels of IL10 (45.6             months), the difference was no longer significant, in contrast to earlier follow-up             data. In conclusion, although serum levels of IL10 may be a prognostic indicator             for HNSCC patients over the short-term, they become less significant as follow-up             time increases.
authors.affiliation: Postgraduate Medical Institute, Castle Hill Hospital, Hull, UK. v.l.green@hull.ac.uk
authors.forename: Victoria L
authors.initials: VL
authors.lastname: Green
authors.forename: Ekpemi
authors.initials: E
authors.lastname: Irune
authors.forename: Amit
authors.initials: A
authors.lastname: Prasai
authors.forename: Osama
authors.initials: O
authors.lastname: Alhamarneh
authors.forename: John
authors.initials: J
authors.lastname: Greenman
authors.forename: Nicholas D
authors.initials: ND
authors.lastname: Stafford
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000276:immunology; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000276:immunology; D006801:Humans; D016753:Interleukin-10 / Q000097:blood* / Q000276:immunology; D018664:Interleukin-12 / Q000097:blood* / Q000276:immunology; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: C508609:IL10 protein, human; C508017:IL2RA protein, human; D053645:Interleukin-2 Receptor alpha Subunit; D016753:Interleukin-10; D018664:Interleukin-12